Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of creatine treatment
in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for
ALS. It is known that nerve cells die in the brains and spinal cords of patients with ALS but
the cause of the cell death is unknown. It has been shown that there is overactive nerve
activity due to increased levels of a chemical called glutamate and that there is abnormal
cellular metabolism along with increased production of substance called "free radicals."
Improving cellular metabolism and readjusting the activity of glutamate in the brain may be
beneficial to ALS patients.
Creatine is a naturally occurring compound, which improves energy metabolism in cells.
Creatine has been given to patients with energy metabolism defects in their muscles, and to
athletes. Creatine improves survival in a mouse model of ALS. Three human subjects with ALS
have received creatine for up to six months without any side effects. Overall, creatine has
been well tolerated and safe.